Finally, we extracted S-overrepresented and NS-overrepresented proteomes and constructed predictive models, which could well distinguish sensitive GC patients from non-sensitive GC patients in response to DOS therapy, XELOX therapy, and anti-HER2 therapy. The gene discussed is ERBB2; the disease is gastric cancer.